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Recently, the miR-34 family has been identified as blocking EMT by downregulating SNAI1 (Kim et al., 2011) , showing its dual function of blocking tumorigenesis and metastasis. Haug et al. found that miR-92 downregulates tumor suppressor DKK3 , which normally inhibits the Wnt signaling pathway. The canonical Wnt signaling can induce EMT mostly by degrading E-cadherin (Heuberger & Birchmeier, 2010) . All this implies that a large network stretching across miR-34, MYCN, and the miR-17-92 cluster is responsible for both tumorogenesis and metastasis in neuroblastoma (Fig. 1) . Hence, miRNAs hold promise as biomarkers for diagnostic and therapeutic purposes. Fig. 1 . Schematic diagram of miRNA network in neuroblastoma tumorigenesis and metastasis, including miR-9 from this study. The dotted box represents our six predicted targets in this study.
The problem remains that miRNAs' small size and similar sequences often make their global expression data noisier than mRNA data. Given that miRNAs regulate the expression of target mRNAs, correlating miRNA with mRNA expression could increase biomarker signals, leading to biomarkers with superior resolution and potentially revealing master regulators. To realize this potential, we need accurate miRNA target identification. While other areas of miRNA research have undergone continuous development, target prediction has lagged behind, partly due to the imperfect miRNA-mRNA bindings found in animals. As experimental and evolutionary evidence indicates that the 5'-end of miRNAs (the nucleotide position 1-8 at the 5'-end, also called the seed sequence) is important for recognition of target sequences in 3'-UTRs (untranslated regions) of mRNA, many computational algorithms utilize only 6-8 nucleotides (nt) of the ~22 mer miRNA to predict target mRNAs. However, there exist many genome-wide sequences matching this short stretch of 6-8 nt, resulting in a large number of false positives among the predicted targets and thus invalidating miRNA-mRNA correlations. Although a database of miRNAs and their experimentally verified targets exists (Papadopoulos et al., 2009) , the list therein is still far from comprehensive. We have identified a new class of miRNA targets, called miBridge, in which the 5'-and 3'-end of a miRNA can simultaneously interact with the 3'-UTR and 5'-UTR of a single mRNA (Lee et al., 2009 ). We will use the terms "3UTR:5emiR" (a miRNA seed sequence and its target site on the 3'-UTR: conventional knowledge) and "5UTR:3emiR" (the 3'-end of a miRNA-the other side of the seed region-and its recognition site in the 5'-UTR: our finding). Whereas other studies have not found global miRNA interactions with the 5'-UTR due to searching against the seed region (5UTR:5emiR), we have found significant 5UTR:3emiR interactions (Ajay, et al., 2010; Lee et al., 2009 ). This sequence-specific miRNA function through 5UTR:3emiR has been experimentally validated (Lee et al., 2009) . In addition to these previous reports establishing the validity and utility of miBridge, we have recently generated a list of genome-wide miBridge targets using version 1 (v.1) prediction parameters. Interestingly, most known miRNA and mRNA (both 5'-UTR and 3'-UTR annotated) have miBridge interactions. Considering both ends of miRNA in the target prediction, miBridge targets are usually fewer in number (about 1/2 to 1/10 of other predictions), while having specific functions which align well with previous expresimental data. In this chapter, we introduce a new approach to identifying miRNAs which differentiates high-risk (advanced) from low-risk neuroblastoma based on expression data and miBridge target predictions. When we applied the method to neuroblastoma patient datasets of mRNA and miRNA expression levels obtained from the Vandesompele group (Mestdagh et al., 2010b) , we found miR-9 to be a consistent biomarker, all six predicted targets being downregulated and their expressions negatively correlated with miR-9 expression. This is interesting since MYCN is one of miR-9's transcription factors, though our analysis did not consider MYCN-amplification status in the advanced stage patient data group. Previous research has shown that miR-9 upregulation correlates with breast cancer metastasis (Ma et al., 2010) , supporting our finding of miR-9 as a new biomarker for advanced neuroblastoma. Furthermore, we also found miR-9 to be significantly upregulated in short-term survival patients within the advanced stage neuroblastoma group in other publicly available data (Scaruffi et al., 2009) , confirming the validity of our finding. To increase the specificity of differentiating high-risk and short-term survival groups, further research is needed to identify additional miR-9 activating factors besides MYCN as well as the common biological pathways of miR-9 target genes in neuroblasts (Fig. 1). www.intechopen.com 
MicroRNA and target gene signature in advanced neuroblastoma
Expression levels of mRNA depend on various factors including DNA copy number, DNA methylation, histone acetylation, active transcription factors, splicing factors, and regulating miRNAs. Here we analyze mRNA expression in a miRNA-centric manner, comparing it with miRNA expression data to increase the specificity of advanced neuroblastoma signatures. This is based on our hypothesis that if a miRNA's function is important and causal to progress neuroblastoma and the expression of the miRNA is up (down)-regulated in the advanced stage, its targets will be preferentially down (up)-regulated in the advanced neuroblastoma. Therefore, we will define a miRNA and its targets as important to the advanced neuroblastoma if such cases are found. Note that this method proceeds without bias of previous knowledge and simply searches for consistent expression data across different datasets (mRNA and miRNA expression), thus allowing novel findings. The Vandesompele group, which has recently identified correlations between MYCNinduced miRNAs and poor outcome in MYCN-activated tumors (Mestdagh et al., 2010b) , kindly provided us matching mRNA and miRNA expression patterns with an annotation file. We also downloaded the mRNA data, disease state, and MYCN amplification status from the Gene Express Omnibus (Series accession number GSE21713). The disease states followed the International Neuroblastoma Staging System's four stages. Stages 1 and 2 indicating the cancer is still localized, while stages 3 and 4 indicate metastasis of the original tumor. To understand global genetic differences in advanced neuroblastoma, we defined two groups for comparison: stage 4 as one group and stage 1 and 2 as another, regardless of MYCN amplification status. Stage 3 data were excluded in order to obtain maximal contrast between the non-metastatic stages and metastatic stage 4. By comparing miRNA and mRNA expression of these two groups, we expected to obtain a more specific advanced neuroblastoma signature, which might not be apparent through mRNA or miRNA analysis alone.
mRNA expression analysis 2.1.1 Differently expressed mRNAs in advanced neuroblastoma
In total, there are 30 primary tumor sample data from 14 stage 4 patients and 16 stage 1 and 2 patients. Briefly, the Vandesomepele group derived the expression data as follows: after each sample expression dataset was obtained using GeneChip Human Exon 1.0 ST Arrays (Affymetrix), all exon data were combined to transcript clusters (hg18/core exons), to obtain expression information per gene after normalization according to the RMA-sketch algorithm using Affymetrix Power Tools. We used these RMA normalized data calculated by the Vandesomepele group to obtain differentially expressed genes between the two groups. Student t-tests were performed using Microsoft Excel functions and mRNA lists with pvalues less than 0.05 were prepared as up-and down-regulated mRNAs using HUGO Gene Nomenclature Committe (HGNC) gene symbol annotation. We ignored transcripts without gene symbol annotation or empty data points among patient samples. If more than two probe sets corresponded to one gene symbol, we chose the probe set with lower p-values. Among a total 372 up-regulated and 689 down-regulated mRNAs with gene symbols having p < 0.05, the top 50 genes with the greatest fold changes are shown in Table 1 . www.intechopen.com
Mapping differentiated mRNAs to regulating miRNAs
For all mRNAs identified as differentially regulated, their regulating miRNAs were predicted using the miBridge miRNA target prediction method (v.1).We then calculated enrichment scores for miRNAs based on their target enrichment tests among the differentially regulated mRNAs. Score over 0 means that the predicted miRNA is significant in the system, 1 being optimal. Table 2 shows the predicted regulating miRNAs (within the miRNA list in the array measured) with target enrichment score over 0. Within the mir-17-92 cluster, hsa-miR-18* targets are enriched in the down-regulated mRNAs, supporting our hypothesis and miRNA target predictions (though miR-92a is not included in this p < 0.05 list, inclusion of genes with less than 15 empty values in patient samples yields a miR-92a score of 0.04 and the prediction that it is up-regulated in advanced neuroblastoma Table 2 . Predicted miRNAs as potential regulators of advanced neuroblastoma (enrichment score > 0).
miRNA expression analysis
The miRNA expression data were obtained from the same patient samples analyzed in the mRNA expression: total 14 stage 4 patients and 16 stage 1 and 2 patients. We used the RMA normalized data with 312 mature miRNA annotations as provided by the Vandesomepele group. Student t-test was performed using Microsoft Excel functions; miRNA lists of score > 0 are shown in Table 3 . Table 3 . Differentially expressed miRNAs in the advanced neuroblastoma (student t-test p < 0.05)
We found that two miRNAs predicted as up-regulated with enrichment score > 0, miR-9 and miR-18a*, are actually up-regulated in microarray experiments with student t-test p < 0.05. Since miR-18a* is a minor strand (less present than miR-18a) within the mir-17-92 cluster, we conclude that miR-9 is the most consistent miRNA in terms of its expression and its targets' expression in our analysis. Fig. 2 shows the box plots of miR-9 expressions in advanced and low-risk stage patient samples together with five other miRNAs whose expression values are most significantly changed in up-and down-regulated miRNAs. 
Correlation of mRNA and miRNA expression data
We found miR-9 to have the most consistent signal in terms of miRNA and mRNA expression level changes in advanced neuroblastoma. Note that miRNA expression pattern alone does not justify further in-depth analyses of miR-9 since other miRNAs have higher fold changes or lower p-value. Our approach thus provides a new way to prioritize important miRNAs. Interestingly, miR-9's seven predicted targets genes are found only in the down-regulated genes. However, this does not mean that expressions of miR-9 and its target genes are negatively correlated across entire samples. Fig. 3 shows the Pearson product moment correlation coefficient of miR-9 and its seven target genes across the 30 patient samples. For context, correlations between miR-9 and all mRNA expression are also shown. The correlations of miR-9 and target genes stand out from all other correlations, six of the seven targets being negatively correlated with miR-9. The six negatively correlated predicted targets are AGPAT4, BTBD9, GABBR1, KCNK10, LRRTM4, and S100PBP. Among them, LRRTM4 is in Table 1 , containing top 50 greatest fold change genes. Fig. 4 shows the scatter plots of the two most negatively correlated miR-9 target genes. Though miR-9 can target multiple genes at the same time, the expression of each target gene varies from person to person, so that its function on each target gene might vary among patients. In our analysis, six genes are predicted as functional targets in the neuroblastoma, potentially responsible for disease progression. As an example, some outliers shown in the circle in Fig. 4B are no longer outliers in the S100PBP case in Fig. 4A . Therefore, rather than one miRNA or one miRNA and its target, collective miR-9 targets and miR-9 might allow more accurate prediction of whether a neuroblastoma will progress to advanced stage. Pearson correlation coefficient of miR-9 and S100PBP is -0.53 (A) and that of miR-9 and LRRTM4 is -0.48 (B).
miR-9 signature in short -and long -lived patients
Scaruffi et al. published research on non-coding RNA expressions with regard to outcome in high-risk neuroblastoma (Scaruffi et al., 2009 ). Among 31 high-risk, stage 4 neuroblastoma samples, miRNA expressions came from 17 short-term survivors (dead within 36 months from diagnosis) and 14 long-term survivors (alive with an overall survival time > 36 months) were deposited in GEO (Series accession number GSE16444). We downloaded the data, which were log 2 -transformed and quantile normalized, after obtaining the raw data using miRNA microarray System protocol v. 1.5 (Agilent Tenchnologies). Since they removed probes with less than 50% of detected slops across all arrays, many low signals were not present. We used the downloaded data to identify differential miRNAs between short-and long-term survivor groups. Significance was calculated with a student's t-test (unpaired, two-tailed, unequal variance); miRNAs upand down-regulated in short-term survivors with p-values less than 0.05 are shown in Table 4 . Table 4 . Differentially expressed miRNAs in short-term survivors compared with long-term survivors. All patients had advanced neuroblastoma.
However, if underlying causes exist for advanced neuroblastoma which further lead to short-term survival, we might identify them from a persistent signal in various contexts. We find miR-9, the only miRNA common between Table 3 and 4, to be such a consistent signal. We want to emphasize that miR-9 must be evaluated in connection with target gene expressions. It was found to be the most consistent miRNA in terms of down-regulating target mRNAs when induced. Moreover, its expression differs between short-and long-term survivors. When it comes to identifying miRNA signature from expression data, it is therefore crucial to compare a miRNA's target expression patterns with its own expression. While many studies focus on global correlations between miRNA and mRNA expressions without a clear regulating matrix, our method of assessing consistency clearly helps pinpoint the signature miRNA in the disease progression. Table 4 . Though the p-value of miR-9 is not as low as others, its differentiating power is close to that of miR-758. In Fig. 2 , the miR-9 level itself may not be powerful enough to differentiate advanced stage from low-risk neuroblastoma. Here, the data suggest that the broader range of miR-9 expression in advanced stage is due to its differentiating power between two sub-groups of www.intechopen.com advanced stage patients (absolute number of normalized data in each dataset is not meaningful). In terms of early prognostic power, miR-9 and its targets hold high promise. Further investigation using larger samples is needed.
miR-9 functional model in advanced neuroblastoma
Recently, Ma et al. reported that miR-9 directly targets E-cadherin (CDH1), leading to increased cell motility and invasiveness in breast cancer (Ma et al., 2010) . Though in a different cell type, since the function of CDH1 in solid tumors is the same, we expect miR-9 to function similarly in the neuroblastoma. Moreover, as a MYCN-activated miRNA, miR-9 fits well within the neuroblastoma miRNA networks (Fig. 1) as a function of developing advanced metastasized neuroblastoma. Our identification of miR-9 and its targets thus makes sense functionally as an early prognostic marker for developing high mortality neuroblastoma. Fig. 1 includes miR-9 and CDH1 as a functional model of developing advanced stage neuroblastoma.
Conclusion
We have used our new method to analyze mRNA and miRNA expression data to identify signature miRNA and target genes in stage 4 neuroblastoma. To obtain maximal contrast between the non-metastatic stages and metastatic stage 4, we excluded stage 3 data and combined stage 1 and 2 as low-risk. When we compared advanced and low-risk stage neuroblastoma, miR-9 related expressions had the most consistent data between mRNA and miRNA expression. We also confirmed that six out of the seven predicted targets were negatively correlated with miR-9 expression across entire samples. Furthermore, miR-9 expression was significantly up-regulated in samples from short-term survivors compared with those from long-term survivors within the same advanced-stage neuroblastoma group. In addition to these data-driven analyses, note that miR-9 has been identified as inducing metastasis in breast cancer by targeting E-cadherin. Therefore, our claim of expressions of miR-9 and its targets as a signature of advancing neuroblastoma fits well with previous studies. Further investigation with a larger number of samples is needed.
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